BioSpace News Archive

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, announced that the company granted equity awards to Mardi C. Dier, the Company’s new Senior Vice President and Chief Financial Officer, effective March 11, 2024 and 39 other new employees, in each case with a grant date of March 1, 2024, as equity inducement awards under the terms of the company’s 2023 Inducement Plan.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, 2024, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

scPharmaceuticals Inc. announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 13, 2024, to discuss the financial results for the fourth quarter and full-year 2023 and provide a business update.

Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that Hans van Houte, Nurix’s chief financial officer, and Jason Kantor, Ph.D., Nurix’s chief business officer will participate in the following conferences in March.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the fourth quarter and full year ended December 31, 2023.

Cardiff Oncology, Inc. (Nasdaq: CRDF) today announced publications of five abstracts that will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10, 2024, in San Diego, California.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2023.

Amgen announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that the Company’s senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m. ET in Miami Beach, FL.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.